Top

Journal of Neurology

Published in:

01-05-2018 | Original Communication

Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration

Authors: Shinji Aoyama, Masahiro Mori, Akiyuki Uzawa, Tomohiko Uchida, Hiroki Masuda, Ryohei Ohtani, Satoshi Kuwabara

Published in: Journal of Neurology | Issue 5/2018

Abstract

Background

The risk of developing progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis (MS) patients is related to serum anti-JCV antibody (JCVAb) index. However, the correlation of JCVAb index with other disease-modifying treatments (DMTs) is not well understood.

Objective

In this study, we investigated the JCVAb seropositivity rate/JCVAb indexes and its correlation with clinical profiles in Japanese MS patients, and the relationship between JCVAb indexes and DMTs.

Methods

JCVAb indexes were measured in 149 serum samples from 105 patients with MS. JCVAb indexes and seropositivity, and their correlation with age, sex, disease duration, Kurtzke expanded disability status scale and the duration of the DMTs were evaluated in each patient.

Results

JCVAb was positive in 73 of 105 MS patients. Within 40 fingolimod-treated patients, 27 were positive for JCVAb and JCVAb indexes were positively correlated with the duration of fingolimod treatment. No significant relation was found between JCVAb indexes and the duration of treatment for the other disease-modifying drugs.

Conclusion

JCVAb seropositivity was comparatively high in Japanese MS patients. Fingolimod treatment is likely to increase serum JCVAb index, possibly leading to the development of PML. Therefore, it is advised that JCVAb index should be serially monitored during fingolimod treatment to decrease PML risk.

Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9:438–446CrossRefPubMed

Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I (2017) Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol 11:925–933CrossRef

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goeltz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870–1880CrossRefPubMed

Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:802–812CrossRefPubMed

Bozic C, Richman S, Plavina T, Natarajan A, Scanlon JV, Subramanyam M, Sandrock A, Bloomgren G (2011) Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 70:742–750CrossRefPubMed

Rosenkranz T, Novas M, Terborg C (2015) PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med 372:1476–1478CrossRefPubMed

Baharnoori M, Lyons J, Dastagir A, Koralnik I, Stankiewicz JM (2016) Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 3:e274CrossRefPubMedPubMedCentral

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2010) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2011):292–302

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452CrossRefPubMed

10.

Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68:295–303CrossRefPubMed

11.

Sroller V, Hamšíková E, Ludvíková V, Vochozková P, Kojzarová M, Fraiberk M, Saláková M, Morávková A, Forstová J, Němečková S (2014) Seroprevalence rates of BKV, JCV, and MCPyV polyomaviruses in the general Czech Republic population. J Med Virol 86:1560–1568CrossRefPubMed

12.

Antonsson A, Green AC, Mallitt KA, O’Rourke PK, Pawlita M, Waterboer T, Neale RE (2010) Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol 91:1849–1853CrossRefPubMed

13.

Cambron M, Hadhoum N, Duhin E, Lacour A, Chouraki A, Vermersch P (2017) JCV serology in time: 3 years of follow-up. Acta Neurol Scand 136:54–58CrossRefPubMed

14.

Taguchi F, Kajioka J, Miyamura T (1982) Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera. Microbiol Immunol 26:1057–1064CrossRefPubMed

15.

Tanaka M, Kinoshita M, Tanaka K (2015) Anti-John Cunningham virus index in Japanese patients with multiple sclerosis and neuromyelitis optica-related disorder. Clin Exp Neuroimmunol 6:309–311CrossRef

16.

Bozic C, Subramanyam M, Richman S, Plavina T, Zhang A, Ticho B (2014) Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial. Eur J Neurol 21:299–304CrossRefPubMed

17.

Paz SC, Branco LP, Pereira MAC, Spessotto CV, Fragoso YD (2018) Systematic review of published data on the worldwide prevalence of John Cunningham virus (JCV) in patients with multiple sclerosis. Epidemiol Health (in press)

18.

Gyang TV, Hamel J, Goodman AD, Gross RA, Samkoff L (2016) Fingolimod-associated PML in a patient with prior immunosuppression. Neurology 86:1843–1845CrossRefPubMedPubMedCentral

19.

Killestein J, Vennegoor A, van Golde AE, Bourez RL, Wijilens ML, Wattjes MP (2014) PML-IRIS during fingolimod diagnosed after natalizumab discontinuation. Case Rep Neurol Med 2014:Article ID 307872

20.

Sinnecker T, Othman J, Kühl M, Metz I, Niendorf T, Kunkel A, Paul F, Wuerfel J, Faiss J (2016) Progressive multifocal leukoencephalopathy in a multiple sclerosis patient diagnosed after switching from natalizumab to fingolimod. Case Rep Neurol Med 2016:5876798PubMedPubMedCentral

21.

Raffel J, Gafson AR, Malik O, Nicholas R (2015) Anti-JC virus antibody titres increase over time with natalizumab treatment. Mult Scler 21:1833–1838CrossRefPubMed

22.

Peters J, Williamson E (2017) Natalizumab therapy is associated with changes in serum JC virus antibody indices over time. J Neurol 264:2409–2412CrossRefPubMed

23.

Schwab N, Schneider-Hohendorf T, Pignolet B, Breuer J, Gross CC, Göbel K, Brassat D, Wiendl H (2016) Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurol Neuroimmunol Neuroinflamm 3:e195CrossRefPubMedPubMedCentral

24.

Javed A, Reder AT (2016) Rising JCV-Ab index during natalizumab therapy for MS: inauspicious for a highly efficacious drug. Neurol Neuroimmunol Neuroinflamm 3:e199CrossRefPubMedPubMedCentral

25.

Subei AM, Cohen JA (2015) Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs 29:565–575CrossRefPubMedPubMedCentral

26.

Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355–360CrossRefPubMed

Title: Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration
Authors: Shinji Aoyama
Masahiro Mori
Akiyuki Uzawa
Tomohiko Uchida
Hiroki Masuda
Ryohei Ohtani
Satoshi Kuwabara
Publication date: 01-05-2018
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 5/2018
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-018-8813-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration

Abstract

Background

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2018

Correction to: Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

Induction of disease remission with one cycle of alemtuzumab in relapsing–remitting MS

Macdonald Critchley (1900–1997)

A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study

Acknowledgement to Reviewers 2017

Smoking at time of CIS increases the risk of clinically definite multiple sclerosis